Study Details
Full Title
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy.
Principal Investigator
Daniel
Landi
Protocol Number
PRO00111813
NCT ID
NCT05566795
Phase
III
Enrollment Status
Open to Enrollment